Abstract
The risk of developing treatment-warranted Type 1 retinopathy of prematurity (ROP) might be reduced in preterm infants by modifying certain systemic factors. There are steps that can be taken both early and late in the course of retinal vascular maturation that may potentially reduce an infant’s risk of developing Type 1 ROP. In prethreshold stage 2–3 ROP without plus disease, a combination of supplemental oxygen, correction of severe anemia, and light adaptation to reduce rod photoreceptor oxygen consumption helped us to reduce ROP severity, and encouraged a return to a more physiologic retinal vascular maturation pattern. Thus, it may be possible to reduce the risk of developing Type 1 ROP by making adjustments in certain systemic parameters aimed at reducing retinal hypoxia, thereby gently lowering pathologically elevated levels of vascular endothelial growth factor (VEGF) within the eye.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991;98:576–80.
VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124:619–33.
Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;1:CD009734.
Vogel RN, Strampe M, Fagbemi OE, Visotcky A, Tarima S, Carroll J, et al. Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity. Ophthalmology. 2018;125:444–52.
Toy BC, Schachar IH, Tan GS, Moshfeghi DM. Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmology. 2016;123:2166–75.
Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125:218–26.
Chuluunbat T, Chan RV, Wang NK, Lien R, Chen YP, Chao AN, et al. Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retin. 2016;47:1095–105.
Yonekawa Y, Thomas BJ, Thanos A, Todorich B, Drenser KA, Trese MT, et al. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina. 2017;37:2208–25.
Yonekawa Y, Wu WC, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina. 2018;38:1079–83.
Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37:694–701.
Ells AL, Wesolosky JD, Ingram AD, Mitchell PC, Platt AS. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity. Can J Ophthalmol. 2017;52:468–74.
Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654–6.
Araz-Ersan B, Kir N, Tuncer S, Aydinoglu-Candan O, Yildiz-Inec D, Akdogan B, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Curr Eye Res. 2015;40:585–91.
Kennedy KA, Mintz-Hittner HA, BEAT-ROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22:61–5 e1.
Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE. 2016;11:e0148019.
Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:e20153218.
Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560–76.
Lutty GA, Hasegawa T, Baba T, Grebe R, Bhutto I, McLeod DS. Development of the human choriocapillaris. Eye. 2010;24:408–15.
Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med. 2008;205:491–501.
Melamed S, Ben-Sira I, Ben-Shaul Y. Ultrastructure of fenestrations in endothelial choriocapillaries of the rabbit—a freeze-fracturing study. Br J Ophthalmol. 1980;64:537–43.
Rhee S, Chung JI, King DA, D’amato G, Paik DT, Duan A, et al. Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease. Nat Commun. 2018;9:368.
Hartnett ME, DeAngelis MM. The role of reactive oxygen species and oxidative signaling in retinopathy of prematurity. In: Stratton RD, Hauswirth WW, Gardner TW, editors. Studies on retinal and choroidal disorders. Humana Press, Springer Science; 2012. pp. 559–84 New York.
Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009;24:77–81.
Hellstrom A, Ley D, Hallberg B, Lofqvist C, Hansen-Pupp I, Ramenghi LA, et al. IGF-1 as a drug for preterm infants: a step-wise clinical development. Curr Pharm Des. 2017;23:5964–70.
Hellstrom A, Ley D, Hansen-Pupp I, Hallberg B, Ramenghi LA, Lofqvist C, et al. IGF-I in the clinics: use in retinopathy of prematurity. Growth Horm IGF Res. 2016;30:3175–80.
Gaynon MW. Rethinking STOP-ROP: is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP. Retina. 2006;26:S18–23.
Gaynon MW, Stevenson DK. What can we learn from STOP-ROP and earlier studies? Pediatrics. 2000;105:420–1.
Gaynon MW, Stevenson DK, Sunshine P, Fleisher BE. Supplemental oxygen and light for prethreshold retinopathy of prematurity. In: Shapiro MJ, Biglan AW, Miller MM, editors. Retinopathy of prematurity. Amsterdam/New York: Kugler Publications; 1995. pp. 137–8.
Gaynon MW, Stevenson DK, Sunshine P, Fleisher BE, Landers MB. Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity. J Perinatol. 1997;17:434–8.
Support Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362:1959–69.
Cayabyab R, Arora V, Wertheimer F, Durand M, Ramanathan R. Graded oxygen saturation targets and retinopathy of prematurity in extremely preterm infants. Pediatr Res. 2016;80:401–6.
Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010;125:e1483–92.
Darlow BA, Binenbaum G. Oxygen, weight gain, IGF-1 and ROP: not a straight-forward equation. Acta Paediatr. 2018;107:732–3.
Lundgren P, Hard AL, Wilde A, Lofqvist C, Smith LEH, Hellstrom A. Implementing higher oxygen saturation targets reduced the impact of poor weight gain as a predictor for retinopathy of prematurity. Acta Paediatr. 2018;107:767–73.
STOP-ROP Manual of Procedures. Available from the Emmes Corp. 2000, pp. 31–2 http://pub.emmes.com/study/rop/stop-publications.html.
The STOP-ROP Multicenter Study Group Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105:295–310.
Colaizy TT, Longmuir S, Gertsch K, Abramoff MD, Klein JM. Use of a supplemental oxygen protocol to suppress progression of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2017;58:887–91.
Lundgren P, Athikarisamy SE, Patole S, Lam GC, Smith LE, Simmer K. Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity. Acta Paediatr. 2018;107:759–66.
Arden GB, Sidman RL, Arap W, Schlingemann RO. Spare the rod and spoil the eye. Br J Ophthalmol. 2005;89:764–9.
Cringle SJ, Yu DY, Yu PK, Su EN. Intraretinal oxygen consumption in the rat in vivo. Invest Ophthalmol Vis Sci. 2002;43:1922–7.
Chan-Ling T, Barnett NL, Maccarone R, Provis J, Koina M, Hu P, et al. Dark-rearing (DR) precludes the initiating event in OIR and eliminates the pathology seen in the second phase of disease: rationale for novel non-invasive treatment for ROP. Invest Ophthalmol Vis Sci. 2016;57:37–50.
Löfqvist CA, Najm S, Hellgren G, Engström E, Sävman K, Nilsson AK, et al. Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;36:271–7.
Hartnett ME. The prematurity of recommending particular polyunsaturated fatty acid supplements for retinopathy of prematurity. JAMA Ophthalmol. 2018;36:277–8.
Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev. 2017;11:CD004863.
Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353:839–41.
Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S. Erythropoietin as a retinal angiogenic factor. N Engl J Med. 2005;353:2190–1.
Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–92.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Gaynon, M.W., Wong, R.J., Stevenson, D.K. et al. Prethreshold retinopathy of prematurity: VEGF inhibition without VEGF inhibitors. J Perinatol 38, 1295–1300 (2018). https://doi.org/10.1038/s41372-018-0177-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-018-0177-9